BTIG analyst Ryan Zimmerman has maintained their bullish stance on ISRG stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Zimmerman has given his Buy rating due to a combination of factors including strong revenue and earnings performance by Intuitive Surgical, which exceeded expectations. The company reported a significant year-over-year revenue increase and adjusted earnings per share that surpassed both BTIG and consensus estimates, driven by robust procedure growth. Despite a slight shortfall in system placements, the company’s average selling prices for systems remained strong, and there was expansion into new geographic markets such as Europe and Japan.
Additionally, the broader launch of the Dv5 system in the US and its higher utilization compared to previous models suggest favorable future dynamics. The company also raised its procedure growth guidance for FY25, indicating confidence in continued demand. While macroeconomic factors like trade and Medicaid cuts are approached cautiously, the overall outlook remains positive, with expectations of growing utilization and revenue per procedure. These factors, along with a robust new product cycle and improving scale, contribute to the Buy rating.
In another report released today, Robert W. Baird also maintained a Buy rating on the stock with a $600.00 price target.
ISRG’s price has also changed moderately for the past six months – from $610.450 to $511.000, which is a -16.29% drop .